NEJM publishes final results from phase two study showing vaccines can reduce rate of sustained TB infections

Aeras, a nonprofit organization dedicated to developing vaccines against tuberculosis (TB), today announced the publication of the full results from a Phase 2, randomized, controlled clinical trial of two TB vaccines– the currently available BCG vaccine and an investigational vaccine, H4:IC31–in the New England Journal of Medicine (NEJM).

Go to Source

(Visited 5 times, 1 visits today)

Site Footer

Sliding Sidebar